Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) is expected to be releasing its Q1 2025 earnings data after the market closes on Tuesday, May 6th. Analysts expect Arcutis Biotherapeutics to post earnings of ($0.19) per share and revenue of $64.80 million for the quarter.
Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.19. The business had revenue of $71.36 million during the quarter, compared to analyst estimates of $60.52 million. Arcutis Biotherapeutics had a negative return on equity of 119.11% and a negative net margin of 140.97%. On average, analysts expect Arcutis Biotherapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Arcutis Biotherapeutics Stock Up 4.0 %
ARQT stock traded up $0.59 during mid-day trading on Friday, hitting $15.24. 1,564,919 shares of the company were exchanged, compared to its average volume of 2,373,751. The firm has a market cap of $1.81 billion, a P/E ratio of -8.51 and a beta of 1.67. Arcutis Biotherapeutics has a 1-year low of $6.99 and a 1-year high of $17.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.38 and a current ratio of 2.46. The firm's 50 day simple moving average is $14.69 and its 200 day simple moving average is $13.05.
Insider Buying and Selling at Arcutis Biotherapeutics
In related news, insider Masaru Matsuda sold 8,338 shares of Arcutis Biotherapeutics stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $12.70, for a total transaction of $105,892.60. Following the completion of the transaction, the insider now owns 178,692 shares in the company, valued at approximately $2,269,388.40. This trade represents a 4.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Todd Franklin Watanabe sold 1,500 shares of the company's stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $17.52, for a total value of $26,280.00. Following the completion of the sale, the insider now owns 927,414 shares in the company, valued at $16,248,293.28. This represents a 0.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 46,099 shares of company stock worth $631,256 over the last ninety days. 9.50% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
A number of equities analysts recently weighed in on ARQT shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $20.00 target price on shares of Arcutis Biotherapeutics in a research note on Wednesday, April 9th. Guggenheim reaffirmed a "buy" rating on shares of Arcutis Biotherapeutics in a research report on Thursday, April 3rd. HC Wainwright reissued a "buy" rating and issued a $19.00 target price on shares of Arcutis Biotherapeutics in a research report on Thursday, April 3rd. Mizuho upped their price target on Arcutis Biotherapeutics from $20.00 to $21.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 26th. Finally, The Goldman Sachs Group lifted their price objective on shares of Arcutis Biotherapeutics from $13.00 to $15.00 and gave the company a "neutral" rating in a report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Arcutis Biotherapeutics has an average rating of "Moderate Buy" and a consensus target price of $18.80.
Get Our Latest Analysis on Arcutis Biotherapeutics
About Arcutis Biotherapeutics
(
Get Free Report)
Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.
Further Reading
Before you consider Arcutis Biotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcutis Biotherapeutics wasn't on the list.
While Arcutis Biotherapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
